600165.SH
宁科生物
SSE · Basic Materials · Steel · CN
CNY 3.27
−1.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 468.3M | 444.5M | 345.3M | 285.7M | 604.5M |
| Cost of Revenue | 520.9M | 533.2M | 412.8M | 384.6M | 604.0M |
| Gross Profit | (52.6M) | (88.7M) | (67.5M) | (98.9M) | 509.3K |
| Operating Expenses | |||||
| R&D Expense | 41.8M | 38.5M | 12.5M | 13.9M | 25.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 63.2M | 64.1M | 55.4M | 47.7M | 98.0M |
| Selling & Marketing Expense | 4.8M | 5.4M | 6.0M | 5.2M | 5.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 149.3M | 145.0M | 227.4M | 215.1M | 224.8M |
| Cost and Expenses | 670.3M | 678.2M | 640.2M | 599.7M | 828.8M |
| Operating Income (EBIT) | (108.7M) | (110.4M) | (560.2M) | (493.4M) | (239.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (148.3M) | (158.0M) | (579.1M) | (515.5M) | (243.0M) |
| Income Tax Expense | 5.6M | 4.9M | (2.0M) | (279.3K) | 4.4M |
| Bottom Line | |||||
| Net Income | (90.6M) | (90.4M) | (538.9M) | (464.7M) | (211.0M) |
| Earnings from Cont. Ops | (153.9M) | (162.9M) | (577.0M) | (515.3M) | (247.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (90.6M) | (90.4M) | (538.9M) | (464.7M) | (211.0M) |
| Per Share | |||||
| Basic EPS | (CN¥0.21) | (CN¥0.06) | (CN¥0.79) | (CN¥0.68) | (CN¥0.31) |
| Diluted EPS | (CN¥0.21) | (CN¥0.06) | (CN¥0.79) | (CN¥0.68) | (CN¥0.31) |
| Revenue Per Share | CN¥0.29 | CN¥0.28 | CN¥0.50 | CN¥0.42 | CN¥0.88 |
| Shares | |||||
| Basic Shares Outstanding | 1.6B | 1.6B | 684.8M | 684.4M | 685.0M |
| Diluted Shares Outstanding | 1.6B | 1.6B | 684.8M | 684.4M | 685.0M |
| Profitability Metrics | |||||
| EBITDA | — | 18.1M | (432.2M) | (354.9M) | (115.8M) |
| D&A | — | 128.5M | 127.9M | 138.5M | 123.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026